INTRODUCTION
============

Genome instability is the major cause of many human diseases, including cancer. One of the major sources of genome instability is the loss of a DNA base due to hydrolytic attack of the glycosylic bond linking DNA bases to the sugar phosphate backbone of the DNA molecule ([@gkr744-B1]). These abasic sites (apurinic/apyrimidinic, AP sites) in DNA can also arise as an intermediate product during excision repair of various DNA base lesions. It has been estimated that every single human cell repairs about 10 000 AP sites per day ([@gkr744-B2]) and this highlights the importance of the proteins involved in the repair of this cytotoxic and mutagenic lesion. Human AP endonuclease-1 (APE1, also known as Ref-1) initiates repair of AP sites by incising the phosphodiester bond 5′ to the AP site and generating a DNA single-strand break (SSB) containing a 5′-sugar phosphate residue ([@gkr744-B3],[@gkr744-B4]). This SSB is further repaired by DNA polymerase β and XRCC1--DNA ligase IIIα complex. DNA polymerase β removes the 5′-sugar phosphate residue and adds one undamaged nucleotide into the repair gap. Finally, XRCC1--DNA ligase IIIα complex seals the DNA ends thus accomplishing the repair process ([@gkr744-B5]). Although being a small protein (36 kDa), APE1 has multiple other enzymatic activities, including 3′-phosphatase, 3′-phosphodiesterase and 3′- to 5′-exonuclease activities specific for internal nicks and gaps in DNA ([@gkr744-B6]). It has also been shown to catalyse the release of 3′-phosphoglycolate moieties that block the repair of DNA SSBs ([@gkr744-B7; @gkr744-B8; @gkr744-B9; @gkr744-B10]). All these enzymatic activities of APE1 are important for the repair of DNA lesions induced by oxidative stress and ionising radiation. In addition, APE1 has an important role as a reductive activator of a number of transcription factors, including p53, AP-1, NF-кB and HIF-1α, in response to oxidative stress ([@gkr744-B11]).

APE1 is known to be absolutely required for cellular survival since deletion of APE1 in mice is embryonic lethal ([@gkr744-B12; @gkr744-B13; @gkr744-B14]) and stable cell lines lacking the protein have not been established, again pointing to a critical role for APE1. Down-regulation of APE1 by RNA interference ([@gkr744-B15],[@gkr744-B16]) and the generation of conditional *Ape1* null mice ([@gkr744-B16]) confirmed that AP endonuclease activity is essential for mammalian cell viability and plays a central role in endogenous and induced DNA damage processing. Consequently, controlling the cellular levels of APE1 protein is very important as both over- or under-expression of APE1 leads to genomic instability ([@gkr744-B17; @gkr744-B18; @gkr744-B19]) and is frequently found in cancer cells ([@gkr744-B11],[@gkr744-B20; @gkr744-B21; @gkr744-B22; @gkr744-B23]) and neurological disorders \[([@gkr744-B24]) and references within\].

We have previously demonstrated that the cellular amounts of DNA polymerase β and XRCC1--DNA ligase IIIα, involved in repair of SSBs generated by APE1, are tuned to the amount of DNA damage through regulated proteasomal degradation. This is controlled by the E3 ubiquitin ligases Mule, CHIP and the DNA damage signalling protein and tumour suppressor ARF ([@gkr744-B25],[@gkr744-B26]). However the mechanism controlling APE1 levels is unknown. Assuming that APE1 levels are also controlled by ubiquitylation, we first demonstrated the existence of ubiquitylated APE1 in human cells and then developed an *in vitro* ubiquitylation assay for APE1. Using this assay, we purified UBR3 as the major human E3 ubiquitin ligase targeting APE1 for ubiquitylation, and demonstrate that UBR3 controls the cellular levels of APE1 and is required for genome stability.

MATERIALS AND METHODS
=====================

Antibodies
----------

Polyclonal APE1 antibodies were purified as described ([@gkr744-B27]). APE1 mouse monoclonal antibodies for identification of mouse APE1 (APEX) were purchased from Abcam (Cambridge, UK). ARF and 53BP1 antibodies were purchased from Bethyl Laboratories (Montgomery, USA), tubulin antibodies were from Sigma-Aldrich (Gillingham, UK), Mdm2 antibodies were from Santa Cruz (California, USA) and γ-H2AX antibodies were from Millipore (Watford, UK). Actin, hsp70 and ubiquitin antibodies were purchased from Abcam (Cambridge, UK). UBR3 antibodies were purified as recently described ([@gkr744-B28]).

Plasmids and proteins
---------------------

Ubiquitin, E1 and E2 enzymes were purchased from Boston Biochemicals (Cambridge, USA). pET14b plasmid encoding human APE1 protein was kindly provided by Prof. Hickson and APE1 mutants were constructed using the 'QuikChange' protocol (Stratagene, Amsterdam, Holland) and confirmed by sequencing. Human histidine-tagged APE1 was purified by HisTrap HP column chromatography (GE Healthcare, Little Chalfont, UK). Plasmid encoding mouse APE1 protein (APEX) was kindly provided by Dr Nakabeppu and the *Apex* gene was re-cloned into pCMV3Tag3a plasmid (Agilent Technologies, Stockport, UK). N-terminal FLAG-tagged mouse UBR3 (UBR3) was expressed in *Saccharomyces cerevisiae* SC295 (*MATa, GAL4 GAL80 ura3-52, leu2-3,112 reg1-501 gal1 pep4-3*) from the P*~ADH1~* promoter in a high copy vector as described previously ([@gkr744-B28]). To purify UBR3 protein, the yeast lysate containing UBR3 was mixed with anti-Flag M2 agarose beads (Sigma, Gillingham, UK) and after washing the beads, the bound UBR3 protein was eluted using FLAG peptide-containing elution buffer (200 µg/ml). Purified UBR3 protein was dialyzed against PBS, concentrated and stored at −80°C until required.

Establishment and immortalization of Ubr3^−/−^ mouse embryonic fibroblasts
--------------------------------------------------------------------------

Construction and characterization of *Ubr3*^−^*^/^*^−^ mouse was recently described ([@gkr744-B28]). Primary mouse embryonic fibroblasts (MEFs) were established from wild-type and *Ubr3*^−^*^/^*^−^ embryos at E13.5 in the 129SvImJ/C57BL/6 background as previously described ([@gkr744-B29]). Immortalized MEFs were established from primary MEFs by repeated cell cultures over ∼2 months (∼1.5 × 10^6^ cells onto a 10 cm^2^ plate every 3--5 days).

Whole-cell extracts
-------------------

Whole-cell extracts were prepared by Tanaka\'s method ([@gkr744-B30]). Briefly, cells were resuspended in one packed cell volume of buffer containing 10 mM Tris--HCl (pH 7.8), 200 mM KCl, 1 μg/ml of each protease inhibitor (pepstatin, aprotinin, chymostatin and leupeptin), 1 mM DTT and 1 mM PMSF. Two packed cell volumes of buffer containing 10 mM Tris--HCl (pH 7.8), 600 mM KCl, 40% glycerol, 0.1 mM EDTA and 0.2% Nonidet P-40 was then added and mixed thoroughly before rocking the cell suspension for 2 h at 4°C. The cell lysate was then centrifuged at 40 000 rpm at 4°C for 20 min and the supernatant was collected, aliquoted and stored at −80°C.

Cell fractionation
------------------

Cell fractionation was performed as recently described ([@gkr744-B31]). Briefly, cell pellets were resuspended in two packed cell volumes of buffer containing 20 mM Tris--HCl pH 7.4, 2.5 mM MgCl~2~, 0.5% (v/v) Nonidet P-40, 1 mM PMSF, 1 mM DTT and 1 μg/ml each of aprotinin, pepstatin, chymostatin and leupeptin, and incubated on ice for 10 min. Following centrifugation at 10 000 rpm for 2 min, the supernatant containing cytoplasmic proteins (C) was collected. The nuclear pellet was similarly extracted with two packed cell volumes of buffer containing 20 mM Tris--HCl pH 8.0, 0.5 M KCl, 1 mM EDTA, 0.75% (v/v) Triton X-100, 10% (v/v) glycerol, 1 mM PMSF, 1 mM DTT and 1 μg/ml each of aprotinin, pepstatin, chymostatin and leupeptin and the supernatant containing nuclear proteins (**N**) was collected. For identification of ubiquitylated APE1 bands from HeLa cells, 1 mM NEM was also added to each of the buffers prior to extractions.

Western blots
-------------

Western blots were performed by standard procedure as recommended by the vendor (Novex, San Diego, USA). Blots were visualized using the Odyssey image analysis system (Li-cor Biosciences, Cambridge, UK).

*In vitro* ubiquitylation assay
-------------------------------

*In vitro* ubiquitylation was performed as recently described ([@gkr744-B25]). Briefly, assays were performed in a 15 µl reaction volume in the presence of E1 activating enzyme (0.7 pmol), the indicated E2 conjugating enzymes (9.5 pmol) and ubiquitin (0.6 pmol) or mutant ubiquitin unable to form polyubiquitin chains (Boston Biochem, Cambridge, USA) in buffer containing 25 mM Tris--HCl (pH 8.0), 4 mM ATP, 5 mM MgCl~2~, 200 µM CaCl~2~, 1 mM DTT, 10 µM MG-132 for 1 h at 30°C. SDS--PAGE sample buffer 25 mM Tris-HCl (pH 6.8), 2.5 % beta-mercaptoethanol, 1 % SDS, 5 % glycerol, 1 mM EDTA, 0.15 mg/ml bromophenol blue) was added, the samples were heated for 5 min at 95°C prior to separation of the proteins on a 10% SDS--polyacrylamide gel, followed by transfer to a PVDF membrane and immunoblot analysis with the indicated antibodies.

Partial purification of monoubiquitylated APE1
----------------------------------------------

Whole-cell extracts from 20 g HeLa cells was prepared as described above and dialysed against Buffer A (50 mM Tris, pH 8.0, 1 mM EDTA, 5% glycerol, 1 mM DTT, 1 mM PMSF) containing 150 mM KCl and 1 mM NEM. The dialysate was clarified by centrifugation at 25 000 rpm for 20 min at 4°C, filtered through 0.45 -µm filters and fractionated by Phosphocellulose chromatography using Buffer A containing 150 mM KCl and 1 mM NEM. Proteins were eluted using Buffer A containing 1 M KCl and 1 mM NEM, concentrated and diluted to 50 mM KCl and fractionated by Mono-Q chromatography and the flow-through was collected. Proteins were then fractionated by Mono-S chromatography using Buffer A containing 50 mM KCl and proteins eluted using a linear gradient of 50--1000 mM KCl. Fractions were analysed by 10% SDS--PAGE and immunoblotting with APE1 or ubiquitin antibodies.

Mapping and identification of ubiquitylation sites
--------------------------------------------------

Cleavage of the first 35 amino acids from the APE1 protein for *in vitro* ubiquitylation assays was achieved by treating APE1 (8 µg) with 0.5 µg of trypsin in buffer containing 50 mM Tris--HCl (pH 7.4), 50 mM KCl, 10 mM MgCl~2~ and 1 M urea for 2 h at 23°C. APE1 was then buffer exchanged three times using Amicon Ultra-4 filter units (Millipore, Watford, UK) to remove trypsin and the N-terminal tail of APE1, prior to incubation in the *in vitro* ubiquitylation assay. For identification of ubiquitylation sites, full-length APE1 protein was ubiquitylated *in vitro* using UbcH2 E2 conjugating enzyme as described above, separated by SDS--PAGE and the Coomassie stained band corresponding to monoubiquitylated APE1 was excised, digested with trypsin and analysed by tandem mass spectrometry as recently described ([@gkr744-B26]).

Purification of the E3 ubiquitin ligase for APE1
------------------------------------------------

Cytoplasmic proteins were isolated from 20 g HeLa cells (Cilbiotech, Mons, Belgium) as described above and dialysed against Buffer A (50 mM Tris, pH 8.0, 1 mM EDTA, 5% glycerol, 1 mM DTT, 1 mM PMSF) containing 150 mM KCl. The dialysate was clarified by centrifugation at 25 000 rpm for 20 min at 4°C, filtered through 0.45 -µm filters and applied to a Phosphocellulose column using Buffer A containing 150 mM KCl and the flow-through was collected (PC-FI). PC-FI was concentrated using Vivaflow 50 and 10 kDa MWCO PES membrane modules (Sartorius Stedim, Surrey, UK), diluted 2-fold to achieve a final concentration of 75-mM KCl in the fraction and then added to a 20 ml HiLoad Mono-Q Sepharose column (GE Healthcare, Little Chalfont, UK), washed with Buffer A containing 50 mM KCl and proteins eluted using a linear gradient from 50 to 1000 mM KCl. Active fractions were pooled, concentrated using Amicon Ultra-15 filter units (Millipore, Watford, UK) and loaded onto a Superose-12 column (GE Healthcare, Little Chalfont, UK) in Buffer A containing 150 mM KCl. Active fractions were pooled, diluted to 50 mM KCl and loaded onto a 1 ml Mono Q HR 5/5 column (GE Healthcare, Little Chalfont, UK) in buffer A containing 50 mM KCl. Proteins were eluted using a linear gradient of 50--1000 mM KCl. At each chromatography stage, aliquots of the fractions were analysed for E3 ubiquitin ligase activity using APE1 as a substrate and active fractions pooled for the next chromatography step. Active fractions from the final Mono-Q chromatography stage were analysed by tandem mass spectrometry to identify candidate E3 ubiquitin ligases, as recently described ([@gkr744-B26]).

Plasmid transfection
--------------------

Cells were transfected using Lipofectamine 2000 transfection reagent (Invitrogen, Paisley, UK) according to the manufacturer\'s protocol.

RT--PCR analysis
----------------

RNA was prepared from *Ubr3* wild-type and knockout MEFs using the RNeasy kit (Qiagen, Crawley, UK) and cDNA was subsequently generated using the SuperScript RT--PCR system (Invitrogen, Paisley, UK). UBR3, APE1 and actin was amplified using the following primers: 5′-GGGAATATTTGAACTTGATTTAATCTG-3′ and 5′-CCACACTGGACACGACTTCA-3′; 5′-CGGGGAAGAACCCAAGTC-3′ and 5′-TCCTTCTCGGTTTTCTTTGC-3′; 5′-GGAGGGGGTTGAGGTGTT-3′ and 5′-TGTGCACTTTTATTGGTCTCAAG-3′, respectively. Cycling conditions of one cycle at 95°C for 5 min, 25 cycles (or 30 cycles for UBR3) at 95°C for 30 s, 55°C for 20 s and 72°C for 20 s, and one cycle at 72°C for 5 min. PCR products were separated by 2% agarose gel electrophoresis containing SYBR Green (Invitrogen, Paisley, UK) and analysed using the Molecular Imager FX system (Bio-Rad, Hemel Hempstead, UK).

Clonogenic survival assay
-------------------------

*Ubr3* wild-type and knockout MEFs were seeded in triplicate onto 10-cm^2^ dishes at a density of 300 cells/plate and allowed to adhere for 16 h. The cells were then treated with methyl methanesulphonate (MMS; Sigma-Aldrich, Gillingham, UK) for 45 min, the cells were washed twice with PBS, the media replaced and the cells allowed to form colonies over 7 days. Colonies were stained using methylene blue and subsequently counted. The surviving fraction was calculated by normalizing against the colony numbers achieved for the untreated dishes.

Immunostaining
--------------

Subconfluent cell monolayers on coverslips were fixed with 4% paraformaldehyde for 30 min at room temperature, the cells were permeabilized with 0.2% (w/v) Triton X-100 for 10 min at 4°C and blocked at room temperature with 2% (w/v) BSA---Fraction V for 1 h. The coverslips were then incubated overnight at 4°C with primary antibodies raised against APE1 or 53BP1 diluted 1:300 in BSA. The coverslips were washed and incubated in secondary antibodies, Alexa Fluor 488 F(ab′)~2~ fragment of goat anti-rabbit or anti-mouse (Invitrogen, Paisley, UK) for 1 h. Slides were then mounted using Vectashield hard set mounting media containing 4,6-diamidino-2-phenylindole (DAPI; Vector Laboratories, Peterborough, UK) and imaged using the BioRad MRC 600 confocal microscope and 488 nm (FITC) argon laser lines for excitation.

RESULTS
=======

APE1 ubiquitylation in living cells
-----------------------------------

In HeLa cells, the concentration of APE1 protein is much higher in the nucleus, although a substantial amount can also be detected in the cytoplasm ([Figure 1](#gkr744-F1){ref-type="fig"}A). Taking into account that the volume of the cytoplasm is ∼8-fold larger than the volume of the nucleus, the absolute amount of APE1 that can be extracted into cytoplasmic and nuclear fractions is approximately the same ([Figure 1](#gkr744-F1){ref-type="fig"}B). To demonstrate that APE1 ubiquitylation occurs in living cells, we performed cell fractionation in the presence of *N*-ethylmaleimide (NEM), which is an effective inhibitor of deubiquitylation enzymes. We found that in HeLa cell extracts prepared with NEM, in addition to APE itself, immunoblotting with APE1-specific antibodies detected at least three extra protein bands with a molecular weight of between 45 and 60 kDa, but these were only observed in the cytoplasmic fraction ([Figure 1](#gkr744-F1){ref-type="fig"}B). Since the molecular weight of monoubiquitylated APE1 is expected to be ∼44 kDa, the protein with a molecular weight just \<50 kDa that cross-reacted with the APE1 antibodies was considered as a potential candidate for monoubiquitylated APE1 (APE1~ub,~ [Figure 1](#gkr744-F1){ref-type="fig"}B, indicated by arrow). To provide evidence that this protein was APE1~ub~, we partially purified this protein from a cytoplasmic extract of HeLa cells by sequential Phosphocellulose, Mono-Q and Mono-S chromatographies and monitored fractions with APE1 antibodies. Fractions containing the ∼44--50 KDa protein cross-reacting with the APE1 antibodies were then probed with antibodies directed against ubiquitin. We found that fractions containing the ∼44--50 kDa protein cross-reacted with both APE1 ([Figure 1](#gkr744-F1){ref-type="fig"}C) and ubiquitin ([Figure 1](#gkr744-F1){ref-type="fig"}D) specific antibodies. Furthermore, after precipitation of this protein with APE1 antibodies, the precipitated protein still cross-reacted with both APE1 and ubiquitin antibodies ([Figure 1](#gkr744-F1){ref-type="fig"}E). We thus conclude that this ∼44-kDa protein is monoubiquitylated APE1. Figure 1.Purification of ubiquitylated APE1 from human cells. (**A**) HeLa cells were fixed and immunostained with DAPI and APE1 antibodies demonstrating cytoplasmic and nuclear localization of APE1. (**B**) Cytoplasmic and nuclear fractions prepared from HeLa cells were analysed by 10% SDS--PAGE and immunoblotting using the indicated antibodies. Three bands cross-reacting with APE1 antibodies, in addition to the 36 kDa native form of APE1, were present in the cytoplasmic fraction and were predicted to be ubiquitylated APE1. (**C** and **D**) Analysis of Mono-S chromatography fractions purified from HeLa cells analysed by 10% SDS--PAGE and immunoblotting using either (C) APE1 or (**D**) ubiquitin antibodies. (**E**) The peak monoubiquitylated APE1 containing Mono-S fraction (A9) was immunodepleted using APE1 antibodies and the pull-down was then analysed by 10% SDS--PAGE and immunoblotting using either APE1 (left panel) or ubiquitin (right panel) antibodies. Molecular weight markers are indicated on the left hand side of appropriate figures and the positions of monoubiquitylated APE1 (APE1~ub~) are shown.

UBR3 is an E3 ubiquitin ligase for APE1
---------------------------------------

Having established that APE1 ubiquitylation occurs in living cells, we pursued purification of an E3 ubiquitin ligase activity for APE1 from human cell extracts using a series of chromatography columns ([Figure 2](#gkr744-F2){ref-type="fig"}A) and an *in vitro* ubiquitylation assay. We first observed that the majority of APE1 E3 ubiquitin ligase activity was detected in the cytoplasm ([Figure 2](#gkr744-F2){ref-type="fig"}B) and that the activity became very pronounced after gel-filtration over a Superose 12 column ([Figure 2](#gkr744-F2){ref-type="fig"}C). From this column, we determined that the E3 ubiquitin ligase for APE1 was ∼200--400 kDa. We further demonstrated that *in vitro* ubiquitylation of recombinant APE1 is dependent on the presence of both active fraction and ubiquitin ([Figure 2](#gkr744-F2){ref-type="fig"}D, fourth lane) and further established, using wild-type and mutant ubiquitin unable to form polyubiquitin chains, that recombinant APE1 is polyubiquitylated since we observed only a single product of ubiquitylation using mutant ubiquitin ([Figure 2](#gkr744-F2){ref-type="fig"}D, last lane). We also screened nine ubiquitin E2 conjugating enzymes for their ability to mediate ubiquitylation of APE1 and discovered that the ubiquitylation reaction is specific for UbcH2 (human homologue of yeast Ubc8, [Figure 2](#gkr744-F2){ref-type="fig"}E). Proteins from active fractions from the final purification step (Mono-Q column) were subjected to nanoLC--MS/MS tandem mass spectrometry, which revealed UBR3 as a potential E3 ubiquitin ligase involved in UbcH2-dependent APE1 ubiquitylation ([Supplementary Figure S1](http://nar.oxfordjournals.org/cgi/content/full/gkr744/DC1)). Indeed, when active fractions were tested for the presence of UBR3, we found a strong correlation between APE1 ubiquitylation activity in these active fractions ([Figure 3](#gkr744-F3){ref-type="fig"}A, upper panel) and the amount of UBR3 protein detected by immunoblotting ([Figure 3](#gkr744-F3){ref-type="fig"}A, lower panel). To confirm that UBR3 is responsible for APE1 ubiquitylation in the Mono-Q fractions, we immunoprecipitated UBR3 away from active fractions ([Figure 3](#gkr744-F3){ref-type="fig"}B, lower panel) and demonstrated that UBR3-depleted fractions had significantly reduced ubiquitylation activity ([Figure 3](#gkr744-F3){ref-type="fig"}B, upper panel). We next purified recombinant mouse UBR3 protein ([Figure 3](#gkr744-F3){ref-type="fig"}C) and found that it was able to polyubiquitylate APE1 in an *in vitro* ubiquitylation system reconstituted with purified enzymes ([Figure 3](#gkr744-F3){ref-type="fig"}D). Figure 2.Purification of the E3 ubiquitin ligase for APE1. (**A**) Purification scheme for the isolation of the E3 ubiquitin ligase for APE1 from HeLa cells. (**B**) Cytoplasmic and nuclear fractions (8 µg) were prepared from HeLa cells and analysed for *in vitro* ubiquitylation activity for APE1 (2.8 pmol) in the presence of E1 (0.7 pmol), ubiquitin (0.6 nmol) and various E2 enzymes (9.5 pmol). Reactions were separated by 10% SDS--PAGE and analysed by immunoblotting using APE1 antibodies. The major ubiquitylation activity against APE1 can be observed in the cytoplasmic fraction. (**C**) *In vitro* ubiquitylation of APE1 (2.8 pmol) by Superose 12 fractions purified from HeLa cells in the presence of E1 (0.7 pmol), ubiquitin (0.6 nmol) and various E2 enzymes (9.5 pmol). Reactions were separated by 10% SDS--PAGE and analysed by immunoblotting using APE1 antibodies. E3 ubiquitin ligase activity for APE1 corresponds to a protein of molecular weight between 200 and 400 kDa. (**D**) *In vitro* ubiquitylation of APE1 (2.8 pmol) by an active fraction purified from HeLa cells in the presence of E1 (0.7 pmol), various E2 enzymes (9.5 pmol) and ubiquitin (Ub; 0.6 nmol) or mutant ubiquitin (Mut-Ub) unable to form polyubiquitin chains. (**E**) *In vitro* ubiquitylation of APE1 (2.8 pmol) by an active fraction purified from HeLa cells in the presence of E1 (0.7 pmol), ubiquitin (Ub; 0.6 nmol) and various E2 enzymes (9.5 pmol each). Reactions (D and E) were separated by 10% SDS--PAGE and analysed by immunoblotting using APE1 antibodies. Molecular weight markers are indicated on the left hand side of appropriate figures and the positions of ubiquitylated APE1 (APE1~ub~) are shown. Figure 3.UBR3 is the E3 ubiquitin ligase for APE1. (**A**) *In vitro* ubiquitylation of APE1 (2.8 pmol) by the final Mono-Q chromatography fractions purified from HeLa cells in the presence of E1 (0.7 pmol), UbcH2 (10.5 pmol) and ubiquitin (0.6 nmol) were analysed by 10% SDS--PAGE and immunoblotting using APE1 antibodies. Fractions containing APE1 ubiquitylation activity were shown to correlate with the presence of UBR3 protein detected by immunoblotting (lower panel). (**B**) The peak APE1 ubiquitylation activity containing fraction from the final Mono-Q chromatography was mock immunodepleted and immunodepleted with UBR3 antibodies. The fraction was subsequently analysed for *in vitro* ubiquitylation of APE1 (2.8 pmol) in the presence of E1 (0.7 pmol), UbcH2 (10.5 pmol) and ubiquitin (0.6 nmol) by 10% SDS--PAGE and immunoblotting using APE1 antibodies (upper panel). Furthermore, the pull-down was analysed by 10% SDS--PAGE and immunoblotting using UBR3 antibodies (lower panel). (**C**) N-terminal Flag-tagged mouse UBR3 was expressed in *S. cerevisiae*, purified and analysed by 4--12% SDS--PAGE and Coomassie staining. (**D**) Purified Flag-tagged mouse UBR3 was analysed for *in vitro* ubiquitylation of APE1 (2.8 pmol) in the presence of E1 (0.7 pmol), UbcH2 (10.5 pmol) and ubiquitin (0.6 nmol) by 10% SDS--PAGE and immunoblotting using APE1 antibodies and UBR3 antibodies (lower panel). Molecular weight markers are indicated on the left hand side of appropriate figures and the positions of ubiquitylated APE1 (APE1~ub~) are shown.

It has recently been reported that Mdm2 is involved in APE1 ubiquitylation ([@gkr744-B33]). Although we found that recombinant Mdm2 is able to ubiquitylate APE1 in an *in vitro* ubiquitylation assay ([Supplementary Figure S2](http://nar.oxfordjournals.org/cgi/content/full/gkr744/DC1)), we discovered that the major ubiquitylation activity for APE1 purified from HeLa cells did not co-purify with Mdm2 protein ([Supplementary Figure S3](http://nar.oxfordjournals.org/cgi/content/full/gkr744/DC1)). We thus conclude that UBR3 is the major human E3 ubiquitin ligase involved in polyubiquitylation of APE1.

UBR3 ubiquitylates several lysines at the N-terminus of APE1
------------------------------------------------------------

APE1 protein contains nine lysines within the 35 amino acid N-terminal region ([Figure 4](#gkr744-F4){ref-type="fig"}A). To test whether these residues are the sites of ubiquitylation, we cleaved off this N-terminal region by controlled trypsin hydrolysis. We demonstrated that in contrast to the full length protein (∼32% of the substrate is ubiquitylated), truncated APE1 lacking the first 35 amino acids from the N-terminus cannot be efficiently ubiquitylated by a UBR3-containing fraction purified from HeLa cells (∼4% of the substrate is ubiquitylated, [Figure 4](#gkr744-F4){ref-type="fig"}B). In support of this finding, nanoLC--MS/MS tandem mass spectrometry of *in vitro* ubiquitylated full length APE1 identified lysines 7, 24, 25, 27, 32 and 35 as targets for ubiquitylation. At least for an *in vitro* reaction, it seems that these lysines are interchangeable ubiquitylation targets for UBR3, since replacement of individual lysines or combinations of two to three lysines with arginines did not significantly reduce ubiquitylation ([Figure 4](#gkr744-F4){ref-type="fig"}C). The ubiquitylation of APE1 by UBR3 only significantly dropped when the majority of lysines (K24, K25, K27, K31, K32 and K35) were replaced with arginines and was completely abolished in the Lysine Less Mutant (LLM), that was constructed by replacement of all but K3 within the first 35 amino acids of APE1 ([Figure 4](#gkr744-F4){ref-type="fig"}C, last lane). Figure 4.Identification of UBR3 ubiquitylation sites within APE1. (**A**) Schematic diagram of the protein structure of APE1 showing the nuclear localization sequences (NL1 and NL2), Ref-1 domain and nuclease domain. Major sites (K7/K24/K25/K27/K32/K35) of ubiquitylation by UBR3 identified by mass spectrometry are shown. (**B**) An N-terminal truncation of APE1 lacking the first 35 amino acids (APE1Δ1-35) was analysed for *in vitro* ubiquitylation, in comparison to full length protein (FL), by an active fraction purified from HeLa cells in the presence of E1 (0.7 pmol), UbcH2 (10.5 pmol) and ubiquitin (0.6 nmol) by 10% SDS--PAGE and immunoblotting using APE1 antibodies. (**C**) Wild-type protein (WT) and APE1 mutants, in which the indicated lysines were mutated to arginines, were analysed for *in vitro* ubiquitylation by an active fraction purified from HeLa cells in the presence of E1 (0.7 pmol), UbcH2 (10.5 pmol) and ubiquitin (0.6 nmol) by 10% SDS--PAGE and immunoblotting using APE1 antibodies.

UBR3 knockout cells have increased levels of APE1 and show genome instability
-----------------------------------------------------------------------------

*Ubr3*-knockout mice have been generated and have previously been shown to have a genetic background-dependent lethality, indicating an essential role for this gene ([@gkr744-B28]). To assess the role of UBR3 in controlling APE1 levels, we prepared cell extracts from wild-type and *Ubr3*-knockout MEFs and found ∼2-fold increase in APE1 levels in *Ubr3*-knockout cells ([Figure 5](#gkr744-F5){ref-type="fig"}A). To exclude that the increase in APE1 levels was due to clonal variability, we further analysed two more independent *Ubr3*-knockout cell lines in comparison to three independent wild-type cell lines and found that the *Ubr3*-knockout cells always contained higher APE1 levels ([Figure 5](#gkr744-F5){ref-type="fig"}B). Interestingly, a cell line generated from a *Ubr3*-heterozygous mouse also contained higher protein levels of APE1 ([Figure 5](#gkr744-F5){ref-type="fig"}B). To further demonstrate that APE1 stability depends on UBR3, we transfected plasmids expressing mouse AP-endonuclease 1 (APEX) into wild-type or *Ubr3*-knockout cells. The level of APEX expression was ∼5-fold higher in *Ubr3*-knockout cells compared to wild-type cells ([Figure 5](#gkr744-F5){ref-type="fig"}C). RT--PCR of the RNA purified from *Ubr3*-knockout cells clearly indicated that the levels of *ape1* mRNA in *Ubr3*-wild-type and *Ubr3*-knockout cells is approximately the same ([Figure 5](#gkr744-F5){ref-type="fig"}D) and shows that modulation of APE1 is at the protein level. These data were further confirmed using real-time PCR that showed only a 1.3 ± 0.1-fold increase in *ape1* mRNA levels in *Ubr3*-knockout cells, in contrast to an at least 2-fold increase in protein level ([Supplementary Figure S4](http://nar.oxfordjournals.org/cgi/content/full/gkr744/DC1)). Figure 5.Cells from *Ubr3*-knockout mice contain elevated levels of APE1 protein. (**A** and **B**) Whole cell extracts from MEFs from several wild-type (WT), *Ubr3*-knockout (KO) and heterozygous mice (HET) were prepared and analysed by 10% SDS--PAGE and immunoblotting using the indicated antibodies (**C**) Wild-type and *Ubr3*-knockout MEFs cells were grown on 10-cm^2^ dishes for 24 h to 70--80% confluency and then transfected with equal amounts of mouse Flag-tagged APE1 (APEX~Flag~) expression plasmid. After 24 h, cells were pelleted by centrifugation, whole cell extracts were prepared and analysed by 10% SDS--PAGE and western blotting with the antibodies indicated. (**D**) RNA was prepared from wild-type and *Ubr3*-knockout MEFs and the levels of APE1, UBR3 and actin mRNA analysed by RT--PCR.

We also noticed that the nuclei of *Ubr3*-knockout cells have significant variations in size and shape, in comparison to wild-type cells, that is an indicator of genetically unstable cells ([Figure 6](#gkr744-F6){ref-type="fig"}A and B), ([@gkr744-B33]). We hypothesized that elevated levels of APE1 in *Ubr3*-knockout cells leads to genomic instability through the imbalance of DNA repair and the generation of excessive SSBs that in turn will be converted into DNA double-strand breaks during replication. In support of this hypothesis, we observed a higher number of spontaneously formed 53BP1 foci ([Figure 6](#gkr744-F6){ref-type="fig"}C and D), as well as higher levels of histone H2AX phosphorylation in *Ubr3*-knockout cells compared to wild-type cells ([Figure 6](#gkr744-F6){ref-type="fig"}E), indicating increased levels of endogenously generated DNA double-strand breaks. If our model is correct, then over-expression of APE1 itself should generate DNA strand breaks by misbalancing the repair of endogenous DNA lesions. Indeed, over-expression of APE1 in HeLa cells induced formation of DNA double-strand breaks as detected by increased phosphorylation of histone H2AX ([Figure 6](#gkr744-F6){ref-type="fig"}F). Imbalance of DNA repair in *Ubr3*-knockout cells should also lead to increased formation of DNA strand breaks after mutagen treatment and these can then increase cell toxicity. Indeed, using clonogenic survival assays we were able to show that *Ubr3* knockout cells, in contrast to the wild-type cells, are more susceptible to the cell killing effects of the DNA alkylating agent MMS ([Figure 6](#gkr744-F6){ref-type="fig"}G), that generates base lesions that are almost entirely dependent on APE1 for their repair. Figure 6.Cells from *Ubr3*-knockout mice are genetically instable. **(A** and **C)** MEFs from wild-type and *Ubr3*-knockout mice were fixed and immunostained with the indicated antibodies and stained with DAPI. (**B**) Graphic presentation of nuclei size distribution in wild-type and *Ubr3*-knockout fibroblasts (500 cell nuclei were evaluated). (**D**) Graphic representation of 53BP1 foci ratios calculated from three individual slides (53BP1 foci were counted from 100 cells/slide). (**E**) Whole-cell extracts from MEFs from wild-type (WT) and *Ubr3*-knockout (KO) mice were prepared and analysed by 10% SDS--PAGE and immunoblotting using the indicated antibodies. (**F**) HeLa cells were grown on 10-cm^2^ dishes for 24 h to 70--80% confluency and then transfected with human Flag-tagged APE1 (APE1~Flag~) expression plasmid. After 24 h cells were pelleted by centrifugation, whole cell extracts were prepared and analysed by 10% SDS--PAGE and western blotting with the antibodies indicated. (**G**) MEFs from wild-type and *Ubr3*-knockout mice were grown on 10-cm^2^ dishes in triplicate and treated with the indicated concentrations of MMS for 45 min and colonies allowed to grow for 7 days. The graph represents the mean surviving fraction normalized against the untreated controls from three independent experiments and the standard errors are shown.

DISCUSSION
==========

APE1 is an essential protein that possesses multiple activities involved in DNA repair and it also operates as a redox factor activating a number of transcription factors, including NF-κB, AP-1 and p53 ([@gkr744-B34]). Several studies have addressed the transcriptional regulation of APE1 however, it is also clear that post-translational modifications of APE1 play a major role in protein activity, stability and localization, although very little is known about the mechanisms involved \[reviewed in ([@gkr744-B35])\].

In this study, we investigated the role of ubiquitylation in the regulation of the steady state levels of APE1 protein and identify both the E2 ubiquitin conjugating enzyme, UbcH2 and the E3 ubiquitin ligase, UBR3, as the major enzymes involved. Previously, it was suggested that ubiquitylation of APE1 is accomplished by Mdm2 ([@gkr744-B32]). However, even though we found that Mdm2 can ubiquitylate APE1 *in vitro*, we were not able to demonstrate that Mdm2 purified from human cell extracts possessed a significant ubiquitylation activity for APE1. Nevertheless, we cannot completely rule out that Mdm2 may serve as a minor backup E3 ubiquitin ligase for APE1 in the absence of UBR3. There is also a possibility that Mdm2, as a major regulator of p53, is involved in transcriptional regulation of APE1 since p53 was implicated in the negative regulation of APE1 transcription ([@gkr744-B36]).

We have previously identified the mouse *Ubr3* gene as one of the ubiquitin ligase family members characterized by the UBR box ([@gkr744-B28],[@gkr744-B29]). The UBR box is a signature unique to all known recognition E3 components (UBR1, UBR2, UBR4 and UBR5) of the mammalian N-end rule pathway, called *N*-recognins \[reviewed in ([@gkr744-B37])\]. The UBR box of mouse UBR1 and UBR2 has been shown to function as a substrate recognition domain required for type-1 (basic; Arg, Lys and His) and type-2 (bulky hydrophobic; Phe, Tyr, Trp, Leu and Ile) destabilizing N-terminal residues of the N-end rule pathway ([@gkr744-B29],[@gkr744-B38]). Although UBR3 shares several domains and sequence similarities with UBR1 (25% identity, 51% similarity) and UBR2 (25% identity, 48% similarity), UBR3 apparently does not exhibit *N*-recognin activities, suggesting that UBR3 may have a function outside the conventional N-end rule pathway. However, very little is known about its substrates and cellular functions. We now demonstrate that UBR3 is involved in regulation of the steady state levels of APE1 protein by ubiquitylating its N-terminal lysines, thus stimulating its proteasomal degradation. Since APE1 has the N-terminal Met-Pro-Lys sequence and there is no evidence that APE1 is cleaved into a C-terminal fragment bearing a destabilizing N-terminal residue, it appears that UBR3 recognizes APE1 through an alternative degradation signal.

In our studies to demonstrate the effect of ubiquitylation on APE1, we used MEFs generated from mice lacking exon 1 of *Ubr3* and show that a loss of *Ubr3* results in an increased level of APE1. We also show that there is no increase in *ape1* mRNA levels suggesting that this difference in APE1 protein level is due to post-translational regulation. It is still unclear whether accumulation of APE1 in *Ubr3* knockout fibroblasts is due to a lack of mono- or polyubiquitylation, although based on the *in vitro* ubiquitylation data the latter seems more probable and since due to the very high stability of APE1 protein (turnover time \>16 h) neither cycloheximide nor MG132 treatment experiments can be performed. In spite of many attempts, we were also unable to transiently over-express or efficiently knockdown UBR3 in mammalian cells. Although the mechanism preventing UBR3 over-expression is unclear, most probably an excess of UBR3 causes cell toxicity.

While common sense suggests that over-expression of APE1 should result in faster DNA repair, recent data from several laboratories indicates that an uncoordinated increase in one of the repair enzymes of the base excision repair (BER) pathway leads to misbalanced DNA repair and genome instability ([@gkr744-B39]). In the case of excessive APE1, the repair intermediate that would accumulate would be DNA SSBs that arise during BER of damaged DNA bases or direct incision of abasic sites ([@gkr744-B5]). If the amount of SSBs generated by APE1 exceed the repair capacity of the subsequent steps of BER (gap filling by DNA polymerase β and DNA ligation by XRCC1--DNA ligase IIIα complex), these SSBs can then be converted into DNA double-strand breaks during replication. Accumulation of DNA double-strand breaks may result in genomic instability and increased susceptibility to the cell killing effects of DNA damaging agents. The extent to which these events occur would of course be dependent on the cell type affected, since up-regulated downstream BER activity may compensate for the effects of APE1 over-expression and the ultimate effect on cellular survival is furthermore dependent on the double-strand break repair capacity of the affected cell. For the *Ubr3*-knockout cells, which contain higher protein levels of APE1 than the corresponding wild-type cells, we observed the hypothesized effects. First, we found that *Ubr3*-knockout cells exhibit a significant variation in the size and shape of the nucleus, that is a well-known hallmark of genomic instability ([@gkr744-B33]). We next demonstrated that *Ubr*3-knockout cells had a higher number of spontaneous 53BP1 foci and increased levels of γH2AX in response to endogenously generated damage, both indicators for the presence of DNA double-strand breaks ([@gkr744-B40]). We show that this increase is likely due to APE1 over-expression since transient over-expression of APE1 in HeLa cells also show an increase in the levels of γH2AX. Finally, we demonstrate that *Ubr3*-knockout cells are more susceptible to the cell killing effects of the DNA alkylating agent MMS, that generates base damages which are almost entirely dependent on APE1 for their repair.

It appears that precise tuning of the levels of DNA repair enzymes involved in the BER pathway is required for genome stability. Even a moderate misbalance of the equilibrium between BER proteins may lead to accumulation of DNA double-strand breaks and results in genomic instability. This conclusion is supported by previous observations that cell lines stably over-expressing APE1 show genomic instability ([@gkr744-B41]). *Ubr3*-knockout mice were able to be generated depending on the genetic background, which results in early embryonic lethality or neonatal lethality caused by a number of pathologies, although the reason for this at that time remained unclear ([@gkr744-B28]). Our current study may partially explain the observed phenotype of *Ubr3*-knockout mice and it is quite possible that the different abilities of the 1239vImJ and C57BL/6 mice, used to generate the *Ubr3*-knockout mice, to tolerate DNA double-strand breaks may be one of the reasons for the differential effects of the knockout.

In summary, we propose that newly synthesized cytoplasmic APE1 is directly transferred to the nucleus, where it is able to participate in DNA repair. However if the level of APE1 exceeds the amount required for DNA damage repair, then APE1 is ubiquitylated by UBR3 and becomes a target for proteasomal degradation. An important question that remains unanswered is how cells would know whether they need more or less APE1 and to make the decision whether or not to ubiquitylate APE1. In other words, how is the E3 ubiquitin ligase activity of UBR3 on APE1 regulated? It is possible that other post-translational modifications of APE1, including recently reported phosphorylation ([@gkr744-B42]) and acetylation ([@gkr744-B43]), may modulate its stability, activity or subcellular localization in response to DNA damage by controlling UBR3 ubiquitylation and we are currently investigating this hypothesis.
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